Investor Profile: Sanofi Ventures — Thesis, Cheque Size & How to Apply

Chasing Sanofi Ventures funding? You are pitching the corporate venture capital arm of Sanofi, the French pharma giant — an evergreen fund investing since 2012 that has deployed over $800 million across more than 70 biotech and digital health companies. In September 2025 Sanofi added another $625 million, taking total assets over $1.4 billion. If your science could one day become a Sanofi partnership or acquisition, this is your front door.

The Sanofi Ventures funding thesis

Sanofi Ventures calls itself "a strategic venture fund" — it serves as "an entry point to the innovation ecosystem for Sanofi," backing early-stage transformational science "when companies are too early to partner with or acquire." The thesis stays anchored in Sanofi's priorities — immunology, rare diseases, neurology, and vaccines — Managing Director Jason Hafler told BioXconomy, alongside a growing bet on digital health, AI, and data-driven platforms that accelerate drug discovery and clinical development.

Cheque size & stages

The fund invests "across all stages of the private company lifecycle, from Seed to Series B and beyond," leading financings and taking board seats, per the official site. Its evergreen structure means no fixed fund-life pressure — it can hold from seed to IPO. No official cheque-size range is published, so that figure is not publicly disclosed. For scale: the fund led a $70 million Series B for Granite Bio in 2025 and reported three 2024 exits with a combined acquisition value of $3.25 billion.

Notable portfolio

The official "Strategic Wins" list — companies that went on to collaborate with Sanofi itself — includes Kymera Therapeutics (protein degraders), QuantHealth (AI clinical-trial simulation), Evidation and Aetion (real-world evidence), Science37, i2O Therapeutics, Fulcrum Therapeutics (losmapimod), and Immune Design. Recent bets include Splice Bio, Character Bio, and Draig Therapeutics. The wider portfolio page also names Bluebird Bio, Ultragenyx, MacroGenics, Carbon Health, Omada Health, and Empatica. No India-based portfolio company was found on the firm's channels.

Programs & perks

Sanofi Ventures runs no accelerator, fellowship, or public startup-credits programme. The perk is the strategic relationship: its bets have repeatedly matured into full Sanofi collaborations — digital-twin trials with QuantHealth, a losmapimod development deal with Fulcrum, protein-degrader work with Kymera, and RWE partnerships with Aetion and Evidation. A cheque here is also a warm entry into the innovation ecosystem of one of the world's largest pharma companies — and, for the right science, a path to partnership or acquisition.

How to apply for Sanofi Ventures funding

There is no open application portal or published deadline. The official route is direct outreach: the team page on sanofiventures.com invites founders — "We love to meet entrepreneurs… feel free to reach out to us" — with individual contact links per investor. The team is led by Managing Director Jason Hafler (with the firm since 2014) and includes Cris De Luca, formerly of Johnson & Johnson's digital health incubator. Practically, a warm intro through a portfolio founder or co-investor is the strongest route in. Bring a story about transformational science in immunology, rare disease, neurology, vaccines, or AI-driven drug development.